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Mauro Alini, Ph.D.,2 Chiara Bocelli-Tyndall, Ph.D.,1,3 Dirk J. Schaefer, M.D.,4
Ivan Martin, Ph.D.,1 and Arnaud Scherberich, Ph.D.1
Fetal bovine serum (FBS) and fibroblast growth factor (FGF)-2 are key supplements for the culture of stromal
vascular fraction (SVF) cells from adipose tissue, both for typical monolayer (2D) expansion and for streamlined
generation of osteogenic–vasculogenic grafts in 3D perfusion culture. The present study investigates whether
factors present in human platelet lysate (PL) could substitute for FBS and FGF-2 in 2D and 3D culture models of
SVF cells from human lipoaspirates. SVF cells were grown in medium supplemented with 10% FBSþ FGF-2 or
with 5% PL. In 2D cultures, PL initially supported SVF cell proliferation, but resulted in growth arrest shortly after
the first passage. Freshly isolated SVF cells culturedwith bothmedia under perfusion for 5 dayswithin 3D ceramic
scaffolds induced bone formation after subcutaneous implantation in nudemice. However, blood vessels of donor
origin were generated only using FBSþ FGF-2–cultured cells. This was unexpected, because the proportion of
CD34þ=CD31þ endothelial lineage cells was significantly higher with PL than that of FBSþ FGF-2 (33% vs. 3%,
respectively). These results support the use of PL as a substitute of FBSþ FGF-2 for short-term culture of human
SVF cells, and indicate that more specific serum-free formulations are required to maintain a functionally vas-
culogenic fraction of SVF cells expanded under 3D perfusion.
Introduction
Human stromal vascular fraction (SVF) cells derivedfrom adipose tissue constitute a promising source of
adult progenitor cells for autologous cell transplantation and
tissue engineering. These progenitor cells can be obtained
in abundance through minimally invasive, low morbidity–
associated harvest procedures, for example, lipoaspiration,
can extensively proliferate in 2D cultures, and can differen-
tiate into multiple cell types, not only of the mesenchymal
lineage,1,2 but also toward neuronal cells,3 cardiomyocytes,4
or hepatocytes.5 Recently, we have also demonstrated that
mesenchymal and endothelial progenitors from human adi-
pose tissue can be cocultured within 3D porous scaffolds
under perfusion flow, resulting in osteogenic and vasculo-
genic properties after ectopic implantation in nude mice.6
Culture of SVF cells, both in 2D and 3D systems, typically
involves the use ofmedia containing fetal bovine serum (FBS),
often further supplemented with fibroblast growth factor
(FGF)-2,2,6 which was shown to be crucial to maintain their
proliferative and differentiation potential.7,8 FBS is a typical
component of standard culture media because it is a source
of proteins promoting cell adhesion and of various growth
factors stimulating cell proliferation. However, its use in the
engineering of clinically compliant grafts raises concerns. As
internalization of xenogenic FBS components in human
mesenchymal progenitor cells may occur during the culture
period,9 the transplantation of cells cultured with FBS into
immunocompetent organisms opens the risk of immune re-
actions ranging from chronic rejection of transplanted cells to
acute anaphylactic, life threatening immune responses.10,11
Additionally, the use of FBS bears the risk of transmitting
prions as well as other known and unknown pathogens. To
overcome the risk of infection and immune-related diseases,
there have been attempts to replace FBS by autologous serum,
for example, for the culture of mesenchymal stromal cells
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(MSC) derived from bone marrow. Substantial expansion
in autologous serum was reported, particularly in the first
passages,12,13 but not to the extent required to obtain clinically
relevant cell numbers. Recently, platelet lysate (PL) has been
proposed as a potent substitute to FBS. Lysis of platelets re-
leases granules containing various growth factors such as
TGF-b, PDGF, IGF-1, EGF, and VEGF, as well as adhesive
proteins involved in hemostasis (fibronectin and fibrinogen).
PL is generally prepared from human blood according to
standardized clinical-grade procedures and is subjected to
careful and documented screening for most major infectious
pathogens such as HIV, cytomegalovirus, or hepatitis B and C
virus. It can thus be considered as a safe and clinically com-
pliant alternative to bovine serum. Previous studies have
demonstrated successful use of PL for the expansion of MSC
from bone marrow14–16 or umbilical cord blood,17 as well as
for the expansion of endothelial cells.18 Moreover, MSC ex-
panded in the presence of PL were not tumorigenic when
assessed in nude mice.16
In the present study, we investigated whether FBS and
FGF-2 could be replaced by PL for typical expansion of SVF
cells in monolayer on tissue culture plastic, and for 3D culture
within porous scaffolds under perfusion flow. Characteriza-
tion included assessment of cell growth and phenotype of the
2D expanded population, as well as in vivo tests of the oste-
ogenic and vasculogenic capacity of the 3D grafts generated in
the perfusion bioreactor system.
Materials and Methods
Preparation of PL
PL was obtained from seven different aphaeresis samples,
each lot coming from a single donor, collected at the Blood
Transfusion Center (Basel, Switzerland) according to Swiss
legislation. The bags were obtained 4–5 days after collection.
Only samples containing at least 1109 platelets=mL were
selected. PL sampleswere frozen overnight at808C and then
thawed to allow the release of the growth factors from the
platelets. The platelet bodies were eliminated by centrifu-
gation at 900 g, the supernatant constituting the PL. To avoid
gel formation by the PL, 2 IU=mL heparin (Roche, Basel,
Switzerland) was added to the PL medium. Growth factor
concentration was measured in four of the seven PL used in
this study with commercially available enzyme-linked im-
munoabsorbent assay (ELISA) for PDGF and bFGF (antibody
#DHB00D and #HSFB75, respectively, both from R&D Sys-
tems, Abingdon, United Kingdom) and for TGF-b1 (antibody
#559119 from Becton Dickinson, Allschwil, Switzerland) fol-
lowing the procedure recommended by the manufacturer.
Cell isolation
Subcutaneous adipose tissue in the form of lipoaspirates
was obtained from thigh and=or abdominal adipose tissue of
16 healthy donors (all females, 47 23 years old, body mass
index 22.2 2.7 kg=m2) during routine dermolipectomy, after
approval by the internal ethics commission and with in-
formed consent from the patients. The tissue was digested in a
final concentration of 0.075% collagenase type 2 (312U=mg;
Worthington, Lakewood, NJ) for 45min at 378C on an orbital
shaker. The suspension was thereafter centrifuged at 300 g for
10min; the resulting pellet (i.e., the SVF) was washed once
with PBS, resuspended in a-modified Eagle’s medium (a-
MEM) (Gibco Invitrogen, Basel, Switzerland), and finally fil-
tered through a 100-mm strainer (BD Falcon, Allschwill,
Switzerland).
Monolayer cell culture
After isolation from the tissue of origin, nucleated SVF cells
were seeded onto Petri dishes at a density of 2.7103
cells=cm2, in a-MEM supplemented either with 10% FBS and
5 ng=mL FGF-2 (FBSþ FGF-2), or with 5% PL. In some ex-
periments, PL was also supplemented at the concentration of
10%. Cells were cultured for the indicated period of time in a
humidified incubator at 378C and 5%CO2. The first expansion
of SVF cells on tissue culture plastic was defined as p0. The
first passage (p1) was defined as the expansion phase right
after the first replating. The number of clonogenic cells, gen-
erally referred to as colony-forming units-fibroblast, was de-
termined by plating 5102 SVF cells in medium containing
FBSþ FGF-2 in 10-cm-diameter Petri dishes, followed by
counting the colonies visibly stained by crystal violet after 2
weeks. The proliferation rate was determined by counting the
number of cells at the first plating (p0) and at the end of each
subsequent passage (p1, p2, and p3), using a Neubauer
chamber. The average number of cell doublings per day was
defined as the total number of doublings during the culture
period, calculated as the logarithm in base 2 of the ratio be-
tween the final and initial cell numbers, divided by the num-
ber of days in culture. The initial number of cells competent
for adhesion and subsequent proliferation was assumed to
correspond to the number of clonogenic cells, determined for
each primary culture in parallel assays as described above.
Cell culture under perfusion
A perfusion bioreactor system was used for cell seeding
and subsequent culture of freshly isolated cells from adipose
tissue in 3D scaffolds, mostly as described previously.6,19,20
About 3106 SVF cells were perfused for 5 days through
8-mm-diameter, 4-mm-thick Engipore disks of porous hy-
droxyapatite ceramic (Fin-Ceramica, Faenza, Italy; average
porosity of 83 3%) in medium containing either 10% FBS
and 5 ng=mL FGF-2 (FBSþ FGF-2), or 5% PL. The flow rate
of the perfusion through the disk was set at 3mL=min.
Construct implantation and in vivo bone
formation assessment
Constructs from independent experiments, after the 3D
perfusion culture, were implanted ectopically in recipient
nude mice (CD-1 nu=nu, 1 month old; Charles River Labora-
tories, Sulzfeld, Germany) in accordance with institutional
guidelines. Eight weeks after implantation, mice were sacri-
ficed, and the constructs were harvested and fixed overnight
in 4% formalin, decalcified for 3 h with Osteodec (Bio-Optica,
Milano, Italy) under agitation at 378C, paraffin embedded,
and sectioned (7-mm-thick sections) at different levels. Sec-
tions were then stained by hematoxylin–eosin and observed
microscopically.
Immunostaining of human blood vessels
Tissue vascularization by endothelial cells of human ori-
gin was determined by immunohistochemical staining with
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a biotin-conjugated antibody recognizing the human isoform
of CD34 (Chemicon, Hampshire, United Kingdom). After
incubation with ABC–alkaline phosphatase complex (Dako,
Baar, Switzerland), specific staining was revealed using Fast
red from Dako. Sections were counterstained with hema-
toxylin and mounted.
Cytofluorimetric analysis
Cell suspensions were incubated for 30min at 48C with
fluorochrome-conjugated antibodies against the indicated
protein, or an isotype control. All the antibodies were from
Becton Dickinson, Allschwil, Switzerland except for CD105,
which was from Serotec, Du¨sseldorf, Germany. Cells were
washed and resuspended in PBS, and analyzed with a
FACSCalibur flow cytometer.
In vitro osteogenic differentiation
SVF cells at p1 were cultured with osteoinductive medium
for 3 weeks, with medium changes twice a week. Osteogenic
medium consisted of a-MEM supplemented with 10% FBS,
100 nM dexamethasone, 10mM [b]-glycerophosphate, and
0.05mM ascorbic acid-2-phosphate. The cells cultured in a-
MEM with FBSþ FGF-2 served as controls. Cell layers were
washed twice with PBS, fixed for 10min with 4% formalin,
and stained with 2% alizarin red S.
Results
2D monolayer cultures
Concentrations of FGF-2, TGF-b1, and PDGF-AB were
measured in four of the PL used in this study and averaged,
respectively, 0.11 0.05, 56.1 26.6, and 18.3 2.1 ng=mL.
After the first passage in monolayers, corresponding to about
4–5 doublings, SVF cells cultured with FBSþ FGF-2 exhibited
a typical fibroblastic morphology, whereas cells cultured with
PL showed a more elongated, heterogeneous population of
cells, with formation of circular structures (Fig. 1A). Proli-
feration of SVF cells was derived during the first expansion
(p0) and at the first three passages. SVF cells cultured with
FBSþ FGF-2 had an initial doubling rate of 1.0 0.2 dou-
blings=day, as compared to 0.7 0.2 for PL. The proliferation
rate of cells cultured with PL dramatically decreased to
0.14 0.15 doublings=day after the first re-plating (p1) and
further reduced to 0.07 0.05 at p2, and no proliferation was
observed at p3 (Fig. 1B, closed squares). At the corresponding
passages, SVF cells cultured with FBSþ FGF-2 prolifer-
ated steadily, with average proliferation rates of around 0.5
FIG. 1. Comparison between SVF cells
expanded in an FBS-containing medium
supplemented with FGF-2 (FBSþ
FGF-2) and a serum-free medium sup-
plemented only with PL. (A) Micro-
scopic picture showing the morphology
of SVF cells cultured on tissue culture
plastic, at p1. (B) Proliferation rate of
SVF cells on tissue culture plastic at
different passages (from p0 to p3, as
indicated), expressed as number of cell
doubling per day. Open circles,
FBSþ FGF-2; closed squares, PL; closed
triangles, SVF cells initially expanded
with FBSþFGF-2 until the end of p1 and
thereafter switched to PL. (C) Colony-
forming efficiency of SVF cells at differ-
ent passages (from freshly isolated SVF
cells to p2). Results are expressed as
percentage of colony-forming cells.
Open circles, FBSþ FGF-2; closed
squares, PL. (D) In vitro osteoblastic
differentiation of SVF cells at the end of
p2. SVF cells cultured with either
FBSþ FGF-2 or PL on plastic until p1
were further cultured for 3 weeks and
stained with alizarin red. Top row: FBS-
containing medium supplemented with
osteogenic supplements (dexamethasone,
ascorbate, and b-glycerophosphate).
Bottom row: FBS-containing medium
only. Color images available online at
www.liebertonline.com=ten.
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doubling=day (Fig. 1B, open circles). When SVF cells ex-
panded with FBSþ FGF-2 until p2 were switched to serum-
free medium containing PL only, the cell expansion rate
dropped immediately to a total arrest after 1–2 passages (Fig.
1B, closed triangles). Neither addition of 5 ng=mLFGF-2 to 5%
PL nor increase of the PL concentration to 10% was able to
prevent the growth arrest of SVF cells at p2.
At each passage, the clonogenic potential of SVF cells was
determined by colony formation assays. Freshly isolated SVF
cells exhibited a 6 3% colony-forming cell frequency, which
remained mostly constant in the range of 5–10% in the cul-
tures until p2, with no significant differences between PL and
FBSþ FGF-2 (Fig. 1C). The clonogenic frequency remained
similar also if SVF cells were expanded with PL further sup-
plemented with 5 ng=mL FGF-2 (9 3%, n¼ 3 independent
donors). At different passages, the differentiation potential of
expanded SVF cells was evaluated by in vitro mineralization
assay. After exposure to osteogenic supplements, SVF cells
expanded until p2 using PL or FBSþ FGF-2 deposited ex-
tensive mineralized matrix, as assessed by alizarin red stain-
ing (Fig. 1D).
At different passages in 2D cultures, the phenotype of SVF
cells was investigated by flow cytometry (Fig. 2). The mark-
ers expressed by freshly isolated SVF cells were mostly in
accordance with our previous data.6 In cells expanded with
FBSþ FGF-2, a typical enrichment in mesenchymal lineage
cells, characterized by expression of CD90 and CD105, was
already observed at p0. The mesenchymal cell popula-
tion represented approximately 100% of the cells at p1 and
p2. In cells cultured with PL, despite enrichment in stromal
cells, an important fraction of cells of the endothelial lineage
(33 26% of CD34þ=CD31þ cells) remained present until
the end of p0, and was gradually lost after p1. Double la-
beling for CD31 and CD34 indicated that at each passage in
FBSþ FGF-2 medium all cells positive for CD34 were nega-
tive for CD31, whereas in PL medium the cells positive for
CD34 were also all positive for CD31 (data not shown). A
population of cells positive for CD31 and the chemokine
receptor CXCR4 was present at p1 and p2, but only with PL.
This population was of the mesenchymal lineage, as assessed
by positivity for CD90 (data not shown).
3D Perfusion cultures
We next investigated the bone and blood vessel formation
capacity of SVF cells expanded for 5 days within porous
ceramic scaffolds in a 3D perfusion system, bypassing the
typical 2D expansion phase. Cells were cultured either with
FBSþ FGF-2 or with PL only, and the resulting constructs
were assessed using an ectopic in vivo bone and blood vessel
formation model.6 After 8 weeks of implantation, sparse
bone tissue was formed in both experimental condi-
tions (Fig. 3A-D). No bone formation was observed when
cell-free scaffolds were implanted in the same ectopic mod-
el.6 In three independent experiments performed using SVF
cells from three different donors, cells cultured with
FBSþ FGF-2 also produced blood vessels, as documented by
immunostaining for human CD34. In particular, we ob-
served a mix of unstained blood vessels of mouse (recipient)
origin and positively stained blood vessels of human (donor)
origin (Fig. 3E), which were connected to the vasculature of
the host, as indicated by the presence of erythrocytes in
their lumen. Unexpectedly, SVF cells grown under perfusion
for 5 days with PL failed to generate human blood vessels
in vivo, and only mouse-derived blood vessels were visible
(Fig. 3F).
FIG. 2. Cytofluorimetric
analysis of SVF cells and of
SVF cells grown on tissue
culture plastic with the indi-
cated medium, at different
passages from p0 to p2. Re-
sults are expressed as per-
centage of cells positive for the
indicated markers.
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Discussion
The present study provides a proof-of-principle on the
efficacy of PL to substitute for FBSþ FGF-2 in the culture of
human SVF cells in different systems. However, our findings
also highlight potential limits for the use of PL, related to (i) a
reduced extent of cell expansion in 2D cultures and (ii) the
lack of a cell fraction with in vivo vasculogenic capacity in 3D
perfusion cultures.
In 2D cultures on plastic, PL supported growth of SVF cells
at least until the first passage. Interestingly, the proliferation
of SVF cells cultured in the presence of PL for more than one
passage restarted when switching them to a medium sup-
plemented with FBSþ FGF-2, as demonstrated by the transfer
into the clonogenicity assay cultures. This capacity to further
grow even under stringent low-density conditions indicates
the preservation of some features of progenitor cells, and re-
assures the use of PL as a serum substitute, in case only a
limited extent of SVF cells is required. However, the expan-
sion of SVF cells over several passages was not feasible, and
PL induced almost a growth arrest shortly after the first
passage. This result is in apparent conflict with another report
by Mirabet et al. indicating that adipose-derived cells can be
expanded with PL21 over many passages. However, several
points make difficult the comparison of that study with ours,
including the different procedure for preparation of PL (re-
spectively using submersion into liquid nitrogen vs. the use of
a 708C freezer) and the different density of platelets before
lysis (respectively 4109 platelets=mL vs. 1–2109). More-
over, Mirabet et al. assessed the proliferation of SVF cells in
PL-supplemented medium only after a first culture phase in
the presence of FBS, whereas we started the serum-free ex-
pansion immediately after cell isolation, to avoid any possible
contamination from FBS in view of a potential clinical ap-
proach. Concentrations of PDGF-AB and TGF-b1 in the PL
used in the present study were measured and were similar to
those described in other studies22,23 using PL able to support
in vitro expansion of bone marrow–derived stromal cells. It is
thus unlikely that the growth arrest observed here could be
due to improper preparation or storage of PL.
There are promising alternatives to the use of PL for the
serum-free expansion of SVF cells. Kocaoemer et al.24 used
thrombin-activated platelet-rich plasma (tPRP) instead of PL,
based on the assumption that a more physiological activation
of platelets by thrombin should result in a more efficient
cocktail of growth factors, and managed to establish long-
term cultures of SVF cells using a serum-free medium sup-
plemented with tPRP. The performance of pooled human AB
serum was also tested in the same study, and the results
were similar to tPRP or FCS, in accordance with another
report showing that low doses of human serum (0.5%) can
support expansion of SVF cells similarly to 10% FBS.25
Nevertheless, supplementations with PL, tPRP, or human
serum in previous studies were always evaluated in vitro
only and could not fully and reliably document the in vivo
performance of the cells expanded with these different FCS
substitutes. Future studies should aim at investigating the
potential of human serum or tPRP in an in vivo setup like in
the present study.
In addition to several other growth factors, such as PDGF-
AB, PDGF-BB, IGF-1, TGF-b1, EGF, and VEGF, PL contains a
typical concentration of 0.1 ng=mL of FGF-2,23,16 corre-
sponding to a final concentration in the test culture medium
of approximately 5 pg=mL. We found a similar concentration
of FGF-2 in our preparations of PL. Because this concentra-
tion is about 1000-fold lower than that of the FBSþ FGF-2
experimental condition (i.e., 5 ng=mL), we tested whether
further supplementation of FGF-2 to PL could support SVF
cell expansion to a larger extent. The lack of a measurable
effect suggests that low levels of FGF-2 were likely not the
factor responsible for growth arrest of SVF cells, and leaves
open the possibility that in addition to known mitogenic
factors, PL contains also growth inhibitory factors, contrast-
ing the effect of FGF-2 on SVF cells.
SVF cells were initially highly heterogeneous in phenotype,
including mesenchymal-, monocytic-, hemopoietic-, and en-
dothelial-lineage populations. During 2D expansion in either
FBSþ FGF-2 or PL, the majority of the cells were of mesen-
chymal origin, which is consistent with previous reports,26,27
although PL supported the maintenance of a larger fraction of
cells double positive for CD31 and CD34 than FBSþ FGF-2.
Interestingly, a population of cells positive for CXCR4 was
maintained only in the presence of PL. Expression of CXCR4
was reported to be expressed by CD34þ=CD31 cells, impli-
cated in the formation of a vascular network during the de-
velopment of human adipose tissue.28 However, expression
of CXCR4 was here associated to mesenchymal cells (CD90þ)
and not to endothelial progenitors (CD34þ=CD31), indicat-
ing a distinct phenotype and possibly function from that
previously reported.
FIG. 3. Histology of SVF cell–hydroxyapatite constructs
after 8 weeks of ectopic in vivo implantation in nude mouse.
(A–D) Bars 200 mm. Fluorescence pictures (top row) and
hematoxylin–eosin staining (bottom row). (E, F) Bars 100 mm.
Immunohistochemical staining for human CD34. Color
images available online at www.liebertonline.com=ten.
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SVF cells freshly isolated and culturedunder perfusionwithin
porous ceramic scaffolds for 5 days in medium supplemented
with FBSþ FGF-2 or PL were both osteogenic when subcuta-
neously implanted in nude mice. Although the reproducibility
and uniformity of in vivo bone formation in this study were not
extensively investigated, the results provide a proof-of-principle
that PL can be used for the streamlined generation of osteogenic
grafts within perfusion-based bioreactor systems. Using the
same model, we also found that blood vessels of human origin
were formed after culture with FBSþ FGF-2, but not with PL.
This result was rather unexpected because, after 2D expansion,
PL maintained notably more endothelial progenitors
(CD31þ=CD34þ cells) than FBSþ FGF-2 (33% vs. 3%, respec-
tively).Assuminga correspondence of cell phenotypes in 2Dand
3D cultures, one possible explanation could be related to the lack
of CD34þ=CD31 cells in the presence of PL. In fact, it was re-
cently shown that CD34þ=CD31 cells derived from adipose
tissue express pericyticmarkers such asNG2proteoglycan29 and
could thus play a role in vascular stabilization by functional
interaction with endothelial cells. Along this theory, it should be
highlighted that another marker of perivascular cells, namely,
CD146þ, was more largely expressed in the presence of
FBSþ FGF-2 than of PL (42% vs. 12% after the first passage). It is
thus possible that PL is not efficient inmaintaining pericytic cells
resident in the SVF, and this would result in the lack of func-
tionality of the endothelial lineage cells present in the graft. The
consequence of lacking a functional vasculogenic cell fraction in
the presence of PL is currently unclear for the performance of
SVF-derived bone grafts. The issue should be investigated in
models addressing the kinetics of blood vessel formation within
grafts (i.e., skin-fold chamber model30), as well as using larger
constructs, where rapid and efficient vascularization is crucial to
reduce formation of a necrotic core.31
Despite the discussed limitations, PL appears to be a
promising serum substitute for the short-term 2D expansion
of SVF cells and for their culture in 3D perfusion systems. As
concerning the potential amount of expanded cells available
using PL for therapeutic purposes, it has to be considered
that adipose biopsies of 200mL to 1L could be obtained from
a donor for clinical application without significant related
morbidity. Based on the present study, starting from as
few as 100mL of adipose tissue, an average of 20106
SVF cells were isolated, which after 5 days of culture in
PL-supplemented medium would potentially result in the
generation of 2–4107 expanded cells (i.e., 2–4108 if 1 L was
used). This would largely exceed the need of expanded cells
for most of the clinical applications envisioned for adipose-
derived cells. These results support the establishment of a
bone tissue engineering model based on minimally invasive
harvesting adipose tissue, then extracting the SVF cells, and
perfusing them in a bioreactor for 5 days in a serum-free
medium supplemented with possibly autologous PL, to
generate osteogenic grafts for bone replacement. The system
would require only animal-free medium supplements, and
the elimination of the 2D expansion phase would represent a
step forward to the development of streamlined, automated,
and possibly more cost-effective manufacturing processes.
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